202 related articles for article (PubMed ID: 17998695)
1. Trastuzumab: is the new evidence revolutionary?
Munshi A; Singh P; Jalali R
J Cancer Res Ther; 2006; 2(3):144-6. PubMed ID: 17998695
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
3. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
4. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
[TBL] [Abstract][Full Text] [Related]
5. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
Kabe KL; Kolesar JM
Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
Simonds HM; Miles D
Expert Opin Biol Ther; 2007 Apr; 7(4):487-91. PubMed ID: 17373900
[TBL] [Abstract][Full Text] [Related]
8. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
Láng I; Hitre E
Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
McKeage K; Lyseng-Williamson KA
Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
[TBL] [Abstract][Full Text] [Related]
10. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Reed SD; Schulman KA
Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
[No Abstract] [Full Text] [Related]
11. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.
Madarnas Y; Trudeau M; Franek JA; McCready D; Pritchard KI; Messersmith H
Cancer Treat Rev; 2008 Oct; 34(6):539-57. PubMed ID: 18502589
[TBL] [Abstract][Full Text] [Related]
12. Ongoing adjuvant trials with trastuzumab in breast cancer.
Tan AR; Swain SM
Semin Oncol; 2003 Oct; 30(5 Suppl 16):54-64. PubMed ID: 14613027
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
Norum J
Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
Younis T; Skedgel C
Pharmacoeconomics; 2011 May; 29(5):361-5. PubMed ID: 21504237
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
16. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
Chen W; Jiang Z; Shao Z; Sun Q; Shen K
Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
[TBL] [Abstract][Full Text] [Related]
17. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
19. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
20. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]